These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

984 related articles for article (PubMed ID: 31518872)

  • 1. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
    Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
    Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
    Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
    Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM
    Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-495-3p sensitizes BCR-ABL1-expressing leukemic cells to tyrosine kinase inhibitors by targeting multidrug resistance 1 gene in T315I mutated cells.
    Rittavee Y; Artus J; Desterke C; Simanic I; de Souza LEB; Riccaldi S; Coignard S; Ijjeh Y; Hugues P; Bennaceur-Griscelli A; Turhan AG; Foudi A
    Exp Hematol; 2023 Feb; 118():40-52. PubMed ID: 36535407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.
    Hershkovitz-Rokah O; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Raanani P; Shpilberg O; Granot G
    Cancer Lett; 2015 May; 360(2):245-56. PubMed ID: 25697481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein.
    Hershkovitz-Rokah O; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Raanani P; Shpilberg O; Granot G
    Cancer Lett; 2015 Jan; 356(2 Pt B):597-605. PubMed ID: 25305453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia.
    Aranda-Tavío H; Recio C; Martín-Acosta P; Guerra-Rodríguez M; Brito-Casillas Y; Blanco R; Junco V; León J; Montero JC; Gandullo-Sánchez L; McNaughton-Smith G; Zapata JM; Pandiella A; Amesty A; Estévez-Braun A; Fernández-Pérez L; Guerra B
    Biomed Pharmacother; 2021 Dec; 144():112330. PubMed ID: 34673425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and activity of Fyn mediate proliferation and blastic features of chronic myelogenous leukemia.
    Singh MM; Howard A; Irwin ME; Gao Y; Lu X; Multani A; Chandra J
    PLoS One; 2012; 7(12):e51611. PubMed ID: 23284724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia.
    Xu C; Fu H; Gao L; Wang L; Wang W; Li J; Li Y; Dou L; Gao X; Luo X; Jing Y; Chim CS; Zheng X; Yu L
    Oncogene; 2014 Jan; 33(1):44-54. PubMed ID: 23208504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrantly reduced expression of miR-342-5p contributes to CCND1-associated chronic myeloid leukemia progression and imatinib resistance.
    Wu YY; Lai HF; Huang TC; Chen YG; Ye RH; Chang PY; Lai SW; Chen YC; Lee CH; Liu WN; Dai MS; Chen JH; Ho CL; Chiu YL
    Cell Death Dis; 2021 Oct; 12(10):908. PubMed ID: 34611140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
    Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
    Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML).
    Desterke C; Voldoire M; Bonnet ML; Sorel N; Pagliaro S; Rahban H; Bennaceur-Griscelli A; Cayssials E; Chomel JC; Turhan AG
    Exp Hematol; 2018 Aug; 64():71-83.e8. PubMed ID: 29733872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
    Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
    J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia.
    Liu Y; Song Y; Ma W; Zheng W; Yin H
    Leuk Res; 2013 Mar; 37(3):349-56. PubMed ID: 23287430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis.
    Eiring AM; Neviani P; Santhanam R; Oaks JJ; Chang JS; Notari M; Willis W; Gambacorti-Passerini C; Volinia S; Marcucci G; Caligiuri MA; Leone GW; Perrotti D
    Blood; 2008 Jan; 111(2):816-28. PubMed ID: 17925491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research advance on molecular genetics of CML blast crisis].
    Zhu HQ; Zhang S; Liu XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update.
    Bavaro L; Martelli M; Cavo M; Soverini S
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
    Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
    Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.